Rezolute (RZLT)
NASDAQ:RZLT
Want to see RZLT full AI Analyst Report?
RZLT Stock Chart & Stats
$3.46
-$0.34(-6.35%)
At close: 4:00 PM EST
$3.46
-$0.34(-6.35%)
Day’s Range― - ―
52-Week Range$1.07 - $11.46
Previous CloseN/A
Volume107.87K
Average Volume (3M)2.74M
Market Cap
$315.80M
Enterprise Value$287.92M
Total Cash (Recent Filing)$132.94M
Total Debt (Recent Filing)$1.28M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding95,697,685
10 Day Avg. Volume1,456,794
30 Day Avg. Volume2,744,138
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.19K
Enterprise Value/Ebitda-3.26
Forecast
1Y Price Target
$5.00Price Target Upside44.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Expanded Access Clinical BenefitExpanded access experience showed most tumor hypoglycemia patients were able to discontinue intravenous glucose and nutritional support after receiving ersodetug, supporting clinical activity in a real-world hospital setting.
Financial RunwayReported cash on hand may provide a runway to fund ongoing operations under current spending assumptions, reducing near-term financing pressure.
Objective Registrational Endpoint ProspectGlucose infusion rate is an objective, mechanism-aligned measure that may be acceptable as a registrational endpoint and could avoid behaviorally confounded assessments in future trials.
Bears Say
Measurement Confounding And Placebo ResponseAn unusually high placebo response, likely linked to intensive glucose monitoring in ambulatory settings, complicates interpretation of efficacy and could undermine trial outcomes.
Phase 3 Trial Failure ImpactA Phase 3 trial in congenital hyperinsulinism failed to meet its primary endpoint, prompting analysts to remove that indication from valuation models and raising program valuation risk.
Regulatory Evidence RiskFDA emphasis on adequate and well-controlled studies and reluctance to lower evidentiary standards increases the likelihood of requests for additional data or further trials.
Rezolute News
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $1.07 and its highest was $11.46 in the past 12 months.
What is Rezolute’s market cap?
Rezolute’s market cap is $315.80M.
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Sep 10, 2026 which is in 130 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on Feb 12, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.187 by -$0.033.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rezolute have?
Rezolute has 95,697,685 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.187. Following the earnings report the stock price went up 5.785%.
Which hedge fund is a major shareholder of Rezolute?
Currently, no hedge funds are holding shares in RZLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rezolute Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (44.51% Upside)
$5.00 (44.51% Upside)
Blogger Sentiment
Neutral
RZLT Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 5.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.81%
12-Months-Change
Fundamentals
Return on Equity
-64.81%
Trailing 12-Months
Asset Growth
23.77%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
RZLT Stock 12 Month Forecast
Average Price Target
$5.00
▲(44.51% Upside)
Technical Analysis
Ownership Overview
10.95% Insiders
31.91% Mutual Funds
0.04% Other Institutional Investors
48.24% Public Companies and
Individual Investors